ATE537842T1 - Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms - Google Patents
Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinomsInfo
- Publication number
- ATE537842T1 ATE537842T1 AT03740312T AT03740312T ATE537842T1 AT E537842 T1 ATE537842 T1 AT E537842T1 AT 03740312 T AT03740312 T AT 03740312T AT 03740312 T AT03740312 T AT 03740312T AT E537842 T1 ATE537842 T1 AT E537842T1
- Authority
- AT
- Austria
- Prior art keywords
- cytokine
- ifn
- alpha
- compositions
- cell carcinoma
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 title 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 title 1
- 108010002350 Interleukin-2 Proteins 0.000 title 1
- 208000006265 Renal cell carcinoma Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108700012439 CA9 Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000011287 therapeutic dose Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000004797 therapeutic response Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39231102P | 2002-07-01 | 2002-07-01 | |
| PCT/EP2003/006591 WO2004002526A1 (en) | 2002-07-01 | 2003-06-23 | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE537842T1 true ATE537842T1 (de) | 2012-01-15 |
Family
ID=30000842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03740312T ATE537842T1 (de) | 2002-07-01 | 2003-06-23 | Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7632496B2 (de) |
| EP (2) | EP2357005A1 (de) |
| JP (3) | JP5408833B2 (de) |
| AT (1) | ATE537842T1 (de) |
| AU (2) | AU2003280442B2 (de) |
| CA (1) | CA2492057A1 (de) |
| ES (1) | ES2377396T3 (de) |
| WO (1) | WO2004002526A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077081A1 (en) | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| US7632496B2 (en) | 2002-07-01 | 2009-12-15 | Wilex Ag | Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas |
| KR101205289B1 (ko) * | 2004-07-02 | 2012-11-27 | 빌렉스 아게 | Ｇ-250 발현 종양의 개선된 보조제 요법 |
| CA2595959A1 (en) * | 2005-01-27 | 2006-08-03 | Novartis Vaccines And Diagnostics, Inc. | Methods for treating renal cell carcinoma |
| US8466263B2 (en) | 2005-12-02 | 2013-06-18 | Dana-Farber Cancer Institute, Inc. | Carbonic anhydrase IX (G250) anitbodies |
| US8053430B2 (en) * | 2008-10-06 | 2011-11-08 | Haraldsson Boerje | Treatment of renal cell carcinoma |
| JP2013523726A (ja) | 2010-04-01 | 2013-06-17 | オンコレナ エービー | 腎細胞癌の改良された治療 |
| WO2013177187A2 (en) * | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| US10888603B2 (en) | 2016-02-12 | 2021-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cancer cells expressing tumor-associated integrins |
| MX2019014023A (es) | 2017-05-24 | 2020-02-17 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer. |
| US11235032B2 (en) | 2019-01-23 | 2022-02-01 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU6032786A (en) | 1985-07-25 | 1987-01-29 | University Of Minnesota | Detection, imaging and therapy of renal cell carcinoma with monoclonal antibodies in vivo |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5104652A (en) | 1986-11-13 | 1992-04-14 | Sloan-Kettering Institute For Cancer Research | Compositions and method for treatment of cancer using monoclonal antibody against GD3 ganglioside together with IL-2 |
| WO1988008854A1 (en) | 1987-05-06 | 1988-11-17 | Egbert Oosterwijk | Monoclonal antibodies to renal cell carcinoma |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5830452A (en) | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
| US5972353A (en) | 1992-03-11 | 1999-10-26 | Institute Of Virology, Slovak Academy Of Sciences | MN proteins, polypeptides, fusion proteins and fusion polypeptides |
| US6204370B1 (en) | 1992-03-11 | 2001-03-20 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| US6027887A (en) | 1992-03-11 | 2000-02-22 | Institute Of Virology, Solvak Academy Of Sciences | MN gene and protein |
| US6297041B1 (en) | 1992-03-11 | 2001-10-02 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| US6774117B1 (en) | 1992-03-11 | 2004-08-10 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| US5989838A (en) | 1992-03-11 | 1999-11-23 | Institute Of Virology, Slovak Academy Of Sciences | Immunological methods of detecting MN proteins and MN polypeptides |
| US6297051B1 (en) | 1997-01-24 | 2001-10-02 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| US6093548A (en) | 1992-03-11 | 2000-07-25 | Institute Of Virology, Slovak Academy Of Sciences | Detection and quantitation of MN-specific antibodies. |
| US5955075A (en) | 1992-03-11 | 1999-09-21 | Institute Of Virology, Slovak Academy Of Sciences | Method of inhibiting tumor growth using antibodies to MN protein |
| US6069242A (en) | 1992-03-11 | 2000-05-30 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| US5981711A (en) | 1992-03-11 | 1999-11-09 | Institute Of Virology, Slovak Academy Of Sciences | MN-specific antibodies and hybridomas |
| US5387676A (en) | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
| US6509313B1 (en) | 1996-02-28 | 2003-01-21 | Cornell Research Foundation, Inc. | Stimulation of immune response with low doses of cytokines |
| US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| US6239235B1 (en) * | 1997-07-15 | 2001-05-29 | Phillips Petroleum Company | High solids slurry polymerization |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| ES2296412T3 (es) | 1998-10-23 | 2008-04-16 | Institute Of Virology | Gen y proteina mn. |
| FR2793497B1 (fr) | 1999-05-10 | 2003-04-18 | Centre Nat Rech Scient | Anticorps monoclonal dirige contre les cellules de carcinome renal humain |
| CN1359391A (zh) | 1999-07-06 | 2002-07-17 | 哥德－A－基因股份公司 | 重组腺病毒 |
| US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| JP2003535592A (ja) | 2000-06-06 | 2003-12-02 | アイデック ファーマスーティカルズ コーポレイション | ヒトｇｐ３９に対する非アゴニスト抗体、含有する組成物、およびその治療的使用 |
| GB0017720D0 (en) | 2000-07-19 | 2000-09-06 | Got A Gene Ab | Modified virus |
| AU2002238537B8 (en) | 2001-02-07 | 2006-08-24 | Wilex Ag | Hybridoma cell line G250 and its use for producing monoclonal antibodies |
| US20040077081A1 (en) | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| IL158969A0 (en) * | 2001-06-01 | 2004-05-12 | Cornell Res Foundation Inc | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7381801B2 (en) | 2002-02-13 | 2008-06-03 | Ludwig Institute For Cancer Research | Chimerized GM-CSF antibodies |
| US20090162382A1 (en) | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| US7632496B2 (en) | 2002-07-01 | 2009-12-15 | Wilex Ag | Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas |
| KR101205289B1 (ko) | 2004-07-02 | 2012-11-27 | 빌렉스 아게 | Ｇ-250 발현 종양의 개선된 보조제 요법 |
| EP1749839A1 (de) | 2005-07-22 | 2007-02-07 | Novoplant GmbH | Antigen-bindende Polypeptide gegen F4 (K88) fimbriae |
| DK1940881T3 (en) | 2005-10-11 | 2017-02-20 | Amgen Res Munich Gmbh | COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF |
| WO2008091798A2 (en) | 2007-01-22 | 2008-07-31 | Xencor, Inc. | Optimized ca9 antibodies and methods of using the same |
| US8492520B2 (en) | 2007-11-02 | 2013-07-23 | Wilex Ag | Binding epitopes for G250 antibody |
-
2003
- 2003-06-23 US US10/517,338 patent/US7632496B2/en not_active Expired - Lifetime
- 2003-06-23 WO PCT/EP2003/006591 patent/WO2004002526A1/en not_active Ceased
- 2003-06-23 ES ES03740312T patent/ES2377396T3/es not_active Expired - Lifetime
- 2003-06-23 CA CA002492057A patent/CA2492057A1/en not_active Abandoned
- 2003-06-23 JP JP2004516641A patent/JP5408833B2/ja not_active Expired - Fee Related
- 2003-06-23 AT AT03740312T patent/ATE537842T1/de active
- 2003-06-23 EP EP11161152A patent/EP2357005A1/de not_active Ceased
- 2003-06-23 EP EP03740312A patent/EP1524995B1/de not_active Expired - Lifetime
- 2003-06-23 AU AU2003280442A patent/AU2003280442B2/en not_active Ceased
-
2009
- 2009-03-30 AU AU2009201236A patent/AU2009201236B2/en not_active Ceased
- 2009-09-15 US US12/559,839 patent/US8828381B2/en not_active Expired - Lifetime
-
2011
- 2011-01-11 JP JP2011003153A patent/JP2011068696A/ja active Pending
-
2013
- 2013-12-12 JP JP2013257017A patent/JP2014043473A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2357005A1 (de) | 2011-08-17 |
| AU2009201236A1 (en) | 2009-04-23 |
| EP1524995A1 (de) | 2005-04-27 |
| US20050261178A1 (en) | 2005-11-24 |
| AU2003280442B2 (en) | 2009-02-05 |
| WO2004002526A1 (en) | 2004-01-08 |
| US7632496B2 (en) | 2009-12-15 |
| JP2005531620A (ja) | 2005-10-20 |
| JP2011068696A (ja) | 2011-04-07 |
| AU2009201236B2 (en) | 2011-05-26 |
| US8828381B2 (en) | 2014-09-09 |
| CA2492057A1 (en) | 2004-01-08 |
| ES2377396T3 (es) | 2012-03-27 |
| JP2014043473A (ja) | 2014-03-13 |
| JP5408833B2 (ja) | 2014-02-05 |
| EP1524995B1 (de) | 2011-12-21 |
| AU2003280442A1 (en) | 2004-01-19 |
| US20100008888A1 (en) | 2010-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110803T1 (el) | Μεθοδοι θεραπειας για καρκινους που εκφραζουν to cd40 αντιγονο | |
| ATE537842T1 (de) | Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms | |
| NO20071585L (no) | Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte | |
| MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
| DE60324427D1 (de) | Verfahren zur modulation der tubulindeacetylase-aktivität | |
| IS8432A (is) | Mótefni sem bindast viðtaka hvítfrumuboða-4 | |
| EP1506285A4 (de) | Kombinationen aus für einen mit tumornekrosefaktor verwandten apoptose-induzierenden ligandenrezeptor und weiteren therapeutischen agentien | |
| BR0313282A (pt) | Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia | |
| TW200518752A (en) | Combinations of drugs for the treatment of neoplasms | |
| DK1169059T3 (da) | Docetaxel i kombination med rhuMAb HER2 til behandling af cancere | |
| MY146533A (en) | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer | |
| CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
| MXPA04003674A (es) | Uso mejorado de compuesto antitumoral en terapia de cancer. | |
| BR0207443A (pt) | Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina | |
| DK1684770T3 (da) | Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft | |
| EA200801731A1 (ru) | Составы и способы лечения тробмоцитемии | |
| WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
| DE60331827D1 (de) | Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren | |
| WO2006088464A3 (en) | A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection | |
| WO2003061571A3 (en) | Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein | |
| ATE545423T1 (de) | Mittel zur behandlung von lungenkrebs | |
| EA200201154A1 (ru) | Бис(n,n'-бис(2-галоэтил)амино)фосфороамидаты в качестве противоопухолевых агентов | |
| WO2004017919A3 (en) | Use of mullerian inhibiting substance and interferon for treating tumors | |
| EA200600987A1 (ru) | Применение сирамезина в лечении злокачественных опухолей |